Prescribing information

 

   

SANDOSTATIN® LAR®: A long-acting injection administered once-a-month

For gastro-entero-pancreatic neuroendocrine tumours1

Treatment with SANDOSTATIN LAR for tumour control should be continued in the absence of tumour progression.

List icon 1: Clear intestines.

For patients with symptoms associated with functional gastro-entero-pancreatic neuroendocrine tumours

  • Administration of 20 mg SANDOSTATIN LAR, at 4-week intervals
  • Patients on treatment with s.c. SANDOSTATIN LAR should continue at the previously effective dosage for 2 weeks after the first injection of SANDOSTATIN LAR
 

List icon 2: Calendar

For patients in whom symptoms and biological markers are well controlled after 3 months of treatment

  • Dose may be reduced to 10 mg SANDOSTATIN LAR every 4 weeks
 

List icon 3: Stool.

For patients in whom symptoms are only partially controlled after 3 months of treatment

  • Dose may be increased to 30 mg SANDOSTATIN LAR every 4 weeks
 

List icon 4: Brain.

For days when symptoms associated with gastro-entero-pancreatic tumours may increase during treatment with SANDOSTATIN LAR, additional administration of s.c. SANDOSTATIN LAR is recommended at the dose used prior to the SANDOSTATIN LAR treatment

  • This may occur mainly in the first 2 months of treatment until therapeutic concentrations of octreotide are reached
 

List Icon 5: Filled in insestine.

For treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded

  • The recommended dose of SANDOSTATIN LAR is 30 mg administered every 4 weeks
  • Treatment with SANDOSTATIN LAR for tumour control should be continued in the absence of tumour progression
 

For acromegaly

The recommended initial dosing of SANDOSTATIN LAR is 20 mg administered at 4-week intervals for 3 months.1

 

For patients currently receiving s.c. SANDOSTATIN LAR injection

The initial dose of SANDOSTATIN LAR can be given the day after the last dose of s.c. SANDOSTATIN.1 Subsequent dosage adjustment should be based on:

  • Serum growth hormone concentrations
  • GH and IGF-1 concentrations
  • Clinical symptoms
Icon: Syringe and calendar

 

 

Managing SANDOSTATIN LAR dosing over time:

Image of chart detailing Managing SANDOSTATIN LAR dosing over time:

 

Method of administration and preparation:

SANDOSTATIN LAR may only be administered by deep intramuscular injection1

Image detailing there are three important actions in the reconstitution of SANDOSTATIN LAR1

Administration of intramuscular injection for SANDOSTATIN LAR1

 Icon of syringe

SANDOSTATIN LAR may only be administered by deep intramuscular injection. The site of repeat intramuscular injections should be alternated between the left and right gluteal muscle

 
 Icon of syringe

Insert the needle fully into the left or right gluteus at a 90° angle to the skin

 
 Icon of syringe

Slowly pull back the plunger to check that no blood vessel has been penetrated (reposition if a blood vessel has been penetrated)

 
 Icon of syringe

Depress the plunger with steady pressure until the syringe is empty. Withdraw the needle from the injection site and activate the safety guard

 

Image detailing For more information with regards to the administration andpreparation of SANDOSTATION LAR please refer to resources

 

For complete instructions of preparing intramuscular injection for SANDOSTATIN LAR please refer to the Summary of Product Characteristics 

GH, growth hormone; HCP, healthcare professional; IGF-1, insulin growth factor-1; s.c. subcutaneous.

Reference

  1. SANDOSTATIN® LAR® Summary of Product Characteristics. December 2020.
Rate this content: 
No votes yet
UK | May 2021 | 104732
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]